A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

Shouki Bazarbashi, Wen Pin Su, Siew W. Wong, Ramanujam A. Singarachari, Sudhir Rawal, Maria I. Volkova, Diogo A. Bastos

研究成果: Review article同行評審

1 引文 斯高帕斯(Scopus)

摘要

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.

原文English
頁(從 - 到)311-327
頁數17
期刊Oncology and Therapy
9
發行號2
DOIs
出版狀態Published - 2021 12月

All Science Journal Classification (ASJC) codes

  • 腫瘤科

指紋

深入研究「A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries」主題。共同形成了獨特的指紋。

引用此